Grandem 1 Tablet contains Granisetron 1mg, a selective serotonin 5-HT3 receptor antagonist used primarily for the prevention and treatment of nausea and vomiting associated with chemotherapy, radiotherapy, and postoperative conditions. Granisetron acts by blocking serotonin receptors located in the central nervous system and gastrointestinal tract, thereby inhibiting the emetogenic signals triggered by cytotoxic agents or surgical procedures. This medication is indicated for patients undergoing moderately to highly emetogenic chemotherapy regimens and can be administered as part of an antiemetic protocol to improve patient comfort and compliance during cancer treatment. Grandem 1 Tablet is typically well tolerated, with common adverse effects including headache, constipation, and dizziness. It is contraindicated in patients with known hypersensitivity to Granisetron or any of its excipients. Caution is advised when prescribing to patients with hepatic impairment, and dosage adjustments may be necessary. The tablet form allows for convenient oral administration, contributing to ease of use in outpatient settings. Grandem 1 Tablet should be used under medical supervision, with adherence to recommended dosing schedules to maximize efficacy and minimize potential side effects.